SST and breast carcinoma: For instance, a 111In-/90Y-labeled SST analogue, namely DOTA-d-β-Nal1-lanreotide (Dotalan®), has been shown to bind to a broad range of primary human tumors and tumor cell lines including breast cancer cells, presumably through SSTR2-5 [223].